




# Overview of research relevant to PMDT

**Susan van den Hof**

on behalf of GDI research task force

GDI core group meeting, 27 October 2014





# How was overview compiled?

- Short questionnaire sent out to stakeholders including additional suggested key informants
  - Research question, study population, timing, research area
  - GDI core group members
  - GDI-interested research task force members
  - RESIST-TB research group (former research subgroup of MDR-TB WG)
  - TB Alliance, ACTG, LSHTM, MRC, TBPANNET/TBNET, EDCTP, Otsuka, Janssen, ...
- Cross-check with trial group websites: RESIST-TB, TB Alliance, TBTC, ACTG
- Remove overlap in responses

# Response and overview



- 62 ongoing and planned studies included in current overview
- Laboratory support: 9
- Treatment strategies of DR-TB: 24
- Programmatically relevant research: 20
- Epidemiology of DR-TB: 4
- Management of contacts with DR-TB: 5
- This overview will not be complete but should contain the larger and most relevant research projects
- This overview will periodically be updated by the GDI secretariat

# Laboratory support



- Whole Genomic Sequencing (WGS) Mycobacterium tuberculosis from M/XDR-TB patients. Analysing results of WGS in connection with clinical disease (M/XDR-TB) presentation and clinical outcome (Belarus)
- development of MODS for second line DST (LSHTM)
- Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide (China)
- molecular diagnosis of DR TB (TBPANNET)
- lab tools for monitoring treatment outcome (TBPANNET)
- PROVE IT LPA (TREAT TB)

*\* listed are ongoing studies only*

# DR-TB treatment strategy



- STREAM trial on 9-month regimen (MRC)
- Phase III trial delamanid and phase I/II pediatric studies (Otsuka)
- Phase III trial bedaquiline with MDR-TB multi-country registry (Janssen)
- DDI study bedaquiline and delamanid (ACTG)
- One-week EBA Study of higher doses of INH in patients with inhA mutations (ACTG)
- STAND, phase III trial: PaMZ for drug-sensitive (4m) and drug-resistant TB (6m) (TB Alliance)
- Optimal Dose of Levofloxacin for MDR-TB (Opti-Q) (TBTC)
- NIX-TB: a salvage regimen for XDR-TB, bedaquiline, linezolid, PA-824 and PZA (RESIST-TB)
- EBA of AZD5847, a novel oxazolidinone
- END-TB (PIH, under development)
- significance of culture reversion during MDR therapy (LSHTM)
- Biomarker evaluation (TBNET)

*\* Listed is a selection only*

# Programmatically relevant research



- Yield of contact investigation for active TB and latent TB infection in households of patients with multi-drug resistant and drug susceptible tuberculosis in different geographical settings (Aurum)
- Levels of resistance to PZA and MFX (WHO)
- How to ensure the optimal implementation of WHO guidance on the use of bedaquiline in the treatment of MDR–TB (WHO)
- A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes (CDC)
- Effects of an outpatient-based model for MDR-TB case management in Moldova on DR-TB spread/amplification, adherence/outcomes, enhance service capacity and side effect management (Otsuka)

*\* listed are a selection of ongoing studies only*

# Epidemiology



- Determinants of MDRTB epidemic in Europe (TBPANNET)
  - M/XDR-TB in Belarus (participation in TBPANNET WP6 database)
- Role of Xpert in surveillance of drug resistance (WHO)
- Availability, Costs and Affordability of TB drugs for M/XDR-TB patients (TBNET)

*\* listed are ongoing studies only*

# Management of DR-TB contacts

- Predictors of MDR-TB progression (RESIST-TB)
- incidence of secondary disease in MDR and DS contacts (LSHTM)
- Follow up of pediatric contacts of DS TB and DR TB patients for one year (India)

*\* listed are ongoing studies only*